The anti-HER2 antibody trastuzumab and the dual EGFR/HER2 kinase inhibitor lapatinib were used in a phase 2 trial performed at four Italian academic cancer centers; the results were as follows: ORR of 30%, DCR of 74%, with 22% of Grade 3 toxicity (41). This evidence concerns the gene ERBB2 and cancer.